1. Athira acquires rights for lasofoxifene for metastatic breast cancer. 2. Phase 3 ELAINE-3 trial is over 50% enrolled, data expected by mid-2027. 3. Company raised $90 million in private financing to support development. 4. ATHA shares surged 74.49% and hit a new 52-week high. 5. Sermonix deal includes milestone payments up to $100 million.
FAQ
Why Very Bullish?
The positive news regarding the drug acquisition and financing shows strong growth potential. Historical examples include similar rises for companies involved in promising clinical trials.
How important is it?
The article highlights significant advancements in clinical trials and financing, crucial for ATHA's success.
Why Long Term?
The data readout is expected in mid-2027, establishing long-term growth due to strategic clinical development.